48,830
edits
Difference between revisions of "Rhabdomyosarcoma"
Jump to navigation
Jump to search
→IHC: more
m (→IHC: sm fix.) |
(→IHC: more) |
||
| Line 87: | Line 87: | ||
*Myogenin. | *Myogenin. | ||
===Subtyping via IHC<ref name=PST14feb11>PST. 14 February 2011.</ref>=== | ===Subtyping via IHC=== | ||
PST proposes<ref name=PST14feb11>PST. 14 February 2011.</ref> the following (presumably based on Makawitz et al.<ref name=pmid18788888>{{cite journal |author=Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR |title=Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors |journal=Pediatr. Dev. Pathol. |volume=12 |issue=2 |pages=127–35 |year=2009 |pmid=18788888 |doi=10.2350/08-05-0477.1 |url=}}</ref>): | |||
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | {| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | ||
| '''IHC''' | | '''IHC''' | ||
| Line 114: | Line 115: | ||
| +ve | | +ve | ||
|} | |} | ||
A paper bu Wachtel at al.<ref>{{cite journal |author=Wachtel M, Runge T, Leuschner I, ''et al.'' |title=Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry |journal=J. Clin. Oncol. |volume=24 |issue=5 |pages=816–22 |year=2006 |month=February |pmid=16391296 |doi=10.1200/JCO.2005.03.4934 |url=}}</ref> proposes the use of: | |||
* ''AP2beta'' and ''P-cadherin'' +ve in translocation positive alveolar RMS, and | |||
* ''EGFR'' and ''fibrillin-2'' +ve in embryonal RMS and translocation negative alveolar RMS. | |||
==[[Electronmicroscopy]]== | ==[[Electronmicroscopy]]== | ||